Holen Sie sich die Stockscreener-App
0.7015
3.65%
0.0253
Schlusskurs vom Vortag:
$0.6762
Offen:
$0.6725
24-Stunden-Volumen:
987.78K
Relative Volume:
0.93
Marktkapitalisierung:
$74.96M
Einnahmen:
$33.03M
Nettoeinkommen (Verlust:
$-44.63M
KGV:
-1.673
EPS:
-0.4193
Netto-Cashflow:
$-36.18M
1W Leistung:
-5.28%
1M Leistung:
-13.61%
6M Leistung:
-55.64%
1J Leistung:
-74.33%
1-Tages-Spanne:
$0.66
$0.7143
1-Wochen-Bereich:
$0.6593
$0.7426
52-Wochen-Spanne:
$0.6434
$2.955
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
0.7015 | 72.26M | 33.03M | -44.63M | -36.18M | -0.4193 |
ABT
Abbott Laboratories
|
102.47 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.77 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.72 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.40 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Eingeleitet | Stephens | Overweight |
| 2023-11-29 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | BTIG Research | Buy |
| 2021-08-24 | Eingeleitet | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | Stephens | Overweight |
| 2021-08-24 | Eingeleitet | Stifel | Buy |
| 2021-08-24 | Eingeleitet | Wedbush | Outperform |
| 2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
MaxCyte (NASDAQ:MXCT) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Risk On: Will MaxCyte Inc outperform small cap indexes2026 Review & Risk Managed Investment Entry Signals - baoquankhu1.vn
MaxCyte sees Q4 core revenue between $6.6M and $6.7M - MSN
MaxCyte Appoints Parmeet Ahuja as New Chief Financial Officer to Drive Strategic Growth - Minichart
MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook - MSN
MaxCyte, Inc. (MXCT) reports Q4 loss, misses revenue estimates - MSN
MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside - The Globe and Mail
MaxCyte Appoints New Chief Financial Officer Ahuja - TipRanks
MaxCyte appoints Parmeet Ahuja as CFO, succeeding Douglas Swirsky - TradingView
New MaxCyte (NASDAQ: MXCT) CFO Parmeet Ahuja joins from Agilent - Stock Titan
Vanguard disaggregates holdings; reports 0% stake in MaxCyte (MXCT) - Stock Titan
MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Brokerages - MarketBeat
MXCT Earnings History & Surprises | EPS & Revenue Results | MAXCYTE INC (NASDAQ:MXCT) - ChartMill
MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access - TipRanks
MaxCyte ExPERT Platform: Leading Non-Viral Cell Engineering Technology for Next-Generation Cell & Gene Therapy Development - Minichart
MaxCyte 2025 10‑K: Revenue $33.0M, EPS $(0.42) - TradingView
MaxCyte (NASDAQ: MXCT) details 2025 losses and $2B SPL upside - Stock Titan
MXCT: Craig-Hallum Maintains Buy Rating but Lowers Price Target - gurufocus.com
Craig-Hallum cuts MaxCyte stock price target on FY25 headwinds By Investing.com - Investing.com Australia
Craig Hallum Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price - MarketBeat
Stifel cuts MaxCyte stock price target on 2026 revenue guidance - Investing.com
Craig-Hallum cuts MaxCyte stock price target on FY25 headwinds - Investing.com
Stifel cuts MaxCyte stock price target on 2026 revenue guidance By Investing.com - Investing.com Australia
MaxCyte 2025 Financial Results Review - AlphaStreet
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 earnings call transcript - MSN
MaxCyte, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 Earnings Call Transcript - Insider Monkey
MaxCyte Reports 2025 Financial Results, Announces 2026 Revenue Guidance and Expansion in Cell Therapy Platform 1 - Minichart
MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ... By GuruFocus - Investing.com Canada
MaxCyte, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
MaxCyte, Inc. (MXCT) Announces Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript - The Globe and Mail
MaxCyte Q4 Earnings Call Highlights - MarketBeat
MaxCyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: MaxCyte Q4 2025 misses earnings, revenue forecasts - Investing.com
Earnings call transcript: MaxCyte Q4 2025 misses earnings, revenue forecasts By Investing.com - Investing.com South Africa
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook - TipRanks
MaxCyte Inc. (MXCT) Stock Falls on Q4 2025 Earnings - quiverquant.com
MaxCyte (NASDAQ:MXCT) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance - The Manila Times
MaxCyte (NASDAQ: MXCT) 2025 revenue falls and company issues 2026 outlook - Stock Titan
MaxCyte, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
MaxCyte appoints Parmeet Ahuja as CFO - MSN
MaxCyte stock rating reiterated at Market Perform by William Blair - Investing.com UK
MaxCyte, Inc. Appoints Parmeet Ahuja as Chief Financial Officer, Effective March 30, 2026 - marketscreener.com
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer - citybiz.co
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maxcyte Inc-Aktie (MXCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hemrajani Rekha | Director |
Jun 25 '25 |
Sale |
2.09 |
10,684 |
22,378 |
39,893 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
161,811 |
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):